** Shares of Vera Therapeutics VERA.O rise 5.7% to $42.53

** Co says U.S. FDA approved its kidney disease drug Trutakna

** Trutakna is a self-administered injectable treatment approved for patients with immunoglobulin A nephropathy, also known as Berger's disease

** The disease causes abnormal protein buildup in the kidneys and could eventually lead to the organ's failure

** Including session's move, stock down 15% YTD